Scholarlink

Objective <p>To evaluate alternative diagnoses in patients referred to neuroimmunology for evaluation of autoimmune encephalitis (AE) and/or positive neural antibodies.</p> Background <p>With increased awareness of AE, AE misdiagnosis has increased—often from improper suspicion of AE or misinterpretation of clinically irrelevant neural antibodies.</p> Methods <p>We retrospectively evaluated all cases referred to our center for AE evaluation and/or a positive neural antibody. We evaluated&#xa0;the frequency and characteristics of patients eventually diagnosed with an alternative diagnosis.</p> Results <p>A total of&#xa0;119 patients were referred between 2017 and 2024. Twenty-two were referred for a positive neural antibody, and seven for possible antibody-negative AE after testing negative before referral.&#xa0;Eighty-one patients1 were tested by our center after inpatient admission or outpatient referral. Our center deemed antibody testing unnecessary in 9&#xa0;patients. Overall, 74 patients were antibody-positive (62%). An alternative diagnosis was found in 60 patients (50.4%), including 32 with positive neural antibodies, and 28 antibody-negative patients. Of patients with alternative diagnoses, 22 had low-clinical-relevance antibodies: low-titer GAD65 (12), AchG (6), VGCC (5), and double-seronegative VGKC (4). Conversely, 10 had antibodies classically considered highly clinically relevant: high-titer GAD65 (4), GABA-BR (2), NMDAR (1), LGI-1 (1), CASPR2 (1), and GFAP (1). Of these, two had concurrent low-titer GAD65.</p> <p>The most common alternative diagnoses included other immune-mediated disorders (28.3%), somatic symptom disorder (23.3%), primary psychiatric disorders (11.7%), metabolic encephalopathy/myoclonus (5%), neurodegenerative disorders (5%), and at 3.3% each, Down syndrome regression disorder, genetic disorders, neuromuscular disorders, and posterior reversible encephalopathy syndrome.</p> Conclusion <p>Alternative diagnoses are common in patients referred for AE evaluation and include mostly psychiatric and other autoimmune conditions. Alternative diagnoses are not restricted to patients with low-clinical-relevance neural antibodies–they are also seen in patients with high-clinical-relevance antibodies and antibody-negative patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Alternative diagnoses in patients referred to neuroimmunology for autoimmune encephalitis evaluation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Sophia F. Damman,
  • Samhitha M. Rai,
  • Rajeet Shrestha,
  • Aasef G. Shaikh,
  • Hesham Abboud

摘要

Objective

To evaluate alternative diagnoses in patients referred to neuroimmunology for evaluation of autoimmune encephalitis (AE) and/or positive neural antibodies.

Background

With increased awareness of AE, AE misdiagnosis has increased—often from improper suspicion of AE or misinterpretation of clinically irrelevant neural antibodies.

Methods

We retrospectively evaluated all cases referred to our center for AE evaluation and/or a positive neural antibody. We evaluated the frequency and characteristics of patients eventually diagnosed with an alternative diagnosis.

Results

A total of 119 patients were referred between 2017 and 2024. Twenty-two were referred for a positive neural antibody, and seven for possible antibody-negative AE after testing negative before referral. Eighty-one patients1 were tested by our center after inpatient admission or outpatient referral. Our center deemed antibody testing unnecessary in 9 patients. Overall, 74 patients were antibody-positive (62%). An alternative diagnosis was found in 60 patients (50.4%), including 32 with positive neural antibodies, and 28 antibody-negative patients. Of patients with alternative diagnoses, 22 had low-clinical-relevance antibodies: low-titer GAD65 (12), AchG (6), VGCC (5), and double-seronegative VGKC (4). Conversely, 10 had antibodies classically considered highly clinically relevant: high-titer GAD65 (4), GABA-BR (2), NMDAR (1), LGI-1 (1), CASPR2 (1), and GFAP (1). Of these, two had concurrent low-titer GAD65.

The most common alternative diagnoses included other immune-mediated disorders (28.3%), somatic symptom disorder (23.3%), primary psychiatric disorders (11.7%), metabolic encephalopathy/myoclonus (5%), neurodegenerative disorders (5%), and at 3.3% each, Down syndrome regression disorder, genetic disorders, neuromuscular disorders, and posterior reversible encephalopathy syndrome.

Conclusion

Alternative diagnoses are common in patients referred for AE evaluation and include mostly psychiatric and other autoimmune conditions. Alternative diagnoses are not restricted to patients with low-clinical-relevance neural antibodies–they are also seen in patients with high-clinical-relevance antibodies and antibody-negative patients.